Healthcare Industry News: XOMA
News Release - January 12, 2006
XOMA Announces Senior Management AppointmentsBERKELEY, Calif.--(HSMN NewsFeed)--Jan. 12, 2006--XOMA Ltd. (Nasdaq:XOMA ), a leading biopharmaceutical company in therapeutic antibodies, today announced four senior management appointments. Appointments include Robert (Bob) H. Gundel, Ph.D., vice president, scientific corporate development; Mary Haak-Frendscho, Ph.D., vice president, preclinical research and development; Mark White, vice president, cell and analytical development; and Paul Goodson, senior director, investor relations.
"Together, Bob, Mary, Mark and Paul bring a tremendous amount of experience to their new positions, leading functions that are key to maximizing the potential of our comprehensive antibody generation platform and development capabilities and in establishing XOMA as the premier antibody discovery and development company," said John L. Castello, XOMA's chairman, president and chief executive officer. "These are also key positions for managing our current collaborations and developing future ones."
In his new role, Dr. Gundel provides corporate leadership to key areas of XOMA's business, including corporate messaging, business development and specialized projects. Dr. Gundel has more than 20 years experience in the biotechnology and pharmaceutical industries including management positions at Chiron Corporation, Boehringer Ingelheim Pharmaceuticals, Inc. and Bayer Corporation. He joined XOMA in 2002 and most recently served as XOMA's vice president, preclinical development. Dr. Gundel holds Ph.D. and M.S. degrees in physiology from New York Medical College and a B.A. degree in biology from S.U.N.Y. College -- Purchase.
Dr. Haak-Frendscho, who has over 15 years experience in the biotechnology industry, most recently at Abgenix, will serve as XOMA's vice president, preclinical research and development. Dr. Haak-Frendscho joined XOMA in 2003 as senior director, cell and analytical biology. In her new role, Dr. Haak-Frendscho leads XOMA's antibody platform enhancement effort and directs the antibody discovery and preclinical development of XOMA's drug candidates. Dr. Haak-Frendscho did her post doctoral work at Genentech, Inc., received her Ph.D. in immunology from the University of Wisconsin and a B.S. in biology from the University of Michigan.
Mark White was appointed vice president, cell and analytical development in November 2005. In his new role, Mr. White provides strategic leadership in developing and implementing XOMA's cell expression and pharmaceutical/bioanalytical capabilities. Mr. White's career at XOMA spans fifteen years and includes multiple scientific and management positions with increasing responsibility. Most recently he was senior director, cell and analytical development, where he successfully integrated XOMA's cell biology and pharmaceutical development groups. Mr. White holds a B.S. degree in biology from the University of California at San Diego and attended graduate school at the University of Iowa.
Paul Goodson is an investor relations executive with more than 20 years of investor relations and general management experience. He comes to XOMA from Shareholder Value Partners, an investor relations and management consulting firm he founded in 2003. Prior to founding Shareholder Value Partners, Mr. Goodson was vice president of investor relations at Invitrogen Corporation, and was previously president of two research and development firms. As XOMA's senior director, investor relations, he is responsible for developing and managing programs that communicate XOMA's messages to the financial community. Mr. Goodson holds B.S. and M.S. degrees in chemical engineering from Caltech and the University of Wisconsin, respectively and an M.B.A. degree from UCLA.
XOMA is a leader in therapeutic antibodies, with a focus on cancer and immune diseases. XOMA has a royalty interest in RAPTIVAŽ (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Serono, SA) to treat moderate-to-severe plaque psoriasis. XOMA's discovery and development capabilities include antibody phage display, bacterial cell expression, and Human Engineering(TM) technologies, plus a fully integrated drug development and manufacturing infrastructure. XOMA's development collaborators include Chiron Corporation and Lexicon Genetics Incorporated. The company pipeline also includes proprietary programs in preclinical and clinical development. For more information about XOMA's product pipeline and antibody development capabilities and technologies, please visit XOMA's website at http://www.XOMA.com.
Certain statements contained herein concerning current collaborations and product development, or that otherwise relate to future periods, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions that may not prove accurate. Actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry and for companies engaged in the development of new products in a regulated market. These risks, including those related to the results of pre-clinical testing, the timing or results of pending and future clinical trials (including the design and progress of clinical trials; safety and efficacy of the products being tested; action, inaction or delay by the FDA, European or other regulators or their advisory bodies; and analysis or interpretation by, or submission to, these entities or others of scientific data), changes in the status of the existing collaborative relationships, the ability of collaborators and other partners to meet their obligations, market demand for products, scale up and marketing capabilities, competition, uncertainties regarding the status of biotechnology patents, uncertainties as to the cost of protecting intellectual property and risks associated with XOMA's status as a Bermuda company, are described in more detail in the Company's most recent annual report on Form 10-K and in other SEC filings. Consider such risks carefully in considering XOMA's prospects.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.